This full paper has just become available and it is an important topic, unfortunately.
'Refractory CLL has been defined as no response or response lasting < 6 months from last therapy. This subgroup has a very poor outcome, and many trials use this group
as an entry point for early drug development.'
PDF File bloodjournal.hematologylibr...
Ublituximab plus ibrutinib versus ibrutinib alone for patients with relapsed or refractory high-risk chronic lymphocytic leukaemia (GENUINE)Results of Phase II Study of Combination Obinutuzumab, Ibrutinib, and Venetoclax in Treatment-Naïve and Relapsed or Refractory CLL
CAR T was just approved for Relapsed/Refractory CLL/SLL ( Potentially 20% CURE rate)
Phase I/II trial of IPH2201 checkpoint inhibitor in combination with ibrutinib opens for patients with relapsed or refractory CLL
COVID risk to CLL patients with the reopening of schools
